A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
Clinical trial NCT03796858 · COMPLETED
Trial details
- NCT number
- NCT03796858
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-22
- Primary completion
- 2020-11-11
- Enrollment
- 285
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.